×
Humacyte Goodwill and Intangible Assets 2021-2025 | HUMA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Humacyte goodwill and intangible assets from 2021 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
View More
Humacyte Goodwill and Intangible Assets 2021-2025 | HUMA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Humacyte goodwill and intangible assets from 2021 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$225.3B
Amgen (AMGN)
$164.8B
Gilead Sciences (GILD)
$144.5B
Vertex Pharmaceuticals (VRTX)
$120.6B
Bristol Myers Squibb (BMY)
$98.6B
CSL (CSLLY)
$85.4B
GSK (GSK)
$77.5B
Regeneron Pharmaceuticals (REGN)
$60.8B
Alnylam Pharmaceuticals (ALNY)
$42.9B
Argenex SE (ARGX)
$36.2B
BioNTech SE (BNTX)
$27.7B
Royalty Pharma (RPRX)
$20.6B
Insmed (INSM)
$19.7B
Biogen (BIIB)
$19.3B
Illumina (ILMN)
$17.3B
Genmab (GMAB)
$15B
Genmab (GNMSF)
$15B
Incyte (INCY)
$13.6B
Moderna (MRNA)
$13.2B
Exelixis (EXEL)
$12.4B
QIAGEN (QGEN)
$11.5B
BioMarin Pharmaceutical (BMRN)
$11.3B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.2B
Bio-Techne Corp (TECH)
$9.2B
Exact Sciences (EXAS)
$9.1B
Verona Pharma American Depositary Share (VRNA)
$9B
Blueprint Medicines (BPMC)
$8.3B
Legend Biotech (LEGN)
$8B
Roivant Sciences (ROIV)
$7.9B